ফুসফুসৰ কেন্সাৰ (নন-স্মল চেল)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
ক’ত যাব
ভাৰতৰ 12 খন চিকিৎসালয়ে এই ট্ৰায়েলৰ বাবে ৰোগী লৈ আছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
স্পনছৰ: Eli Lilly and Company
ClinicalTrials.gov-ত NCT06890598
ৰেজিষ্ট্ৰীত শেষ আপডেট 7 Oct 2026 · আমি পঢ়িছোঁ 20 Oct 2026